STAMP alters the growth of transformed and ovarian cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  He, Yuanzheng ^a,b   Blackford Jr, John A ^a   Kohn, Elise C ^c   Simons Jr, S Stoney ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b VAN ANDEL INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID RECEPTOR; MESSENGER RNA; NUCLEAR RECEPTOR COACTIVATOR 2; SMALL INTERFERING RNA; STAMP PROTEIN; STEROID RECEPTOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; TTLL5 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PLASMID; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSACTIVATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL LINE; CELL TRANSFORMATION; CYTOLOGY; GENETIC TRANSFECTION; GENETICS; KIDNEY; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

CARRIER PROTEINS; CELL GROWTH PROCESSES; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; KIDNEY; OVARIAN NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 77950682598     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-128     Document Type: Article

References (32)

1. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806. 10.1126/science.1164368, 2848990, 18772397.
2. Wang RS, Yeh S, Tzeng CR, Chang C. Androgen Receptor Roles in Spermatogenesis and Fertility: Lessons from Testicular Cell-Specific Androgen Receptor Knockout Mice. Endocr Rev 2009, 2662628, 19176467.
3. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005, 67:285-308. 10.1146/annurev.physiol.67.040403.115914, 15709960.
4. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, O'Malley BW, Lydon JP. Progesterone involvement in breast development and tumorigenesis--as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 2003, 68:779-787. 10.1016/S0039-128X(03)00133-8, 14667968.
5. Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997, 15:840-852.
6. Akaza H. Current status and prospects of androgen depletion therapy for prostate cancer. Best Pract Res Clin Endocrinol Metab 2008, 22:293-302. 10.1016/j.beem.2008.01.010, 18471787.
7. Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol Annu Rev 2006, 12:269-300. full_text, 17045197.
8. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005, 93:121-125. 10.1016/j.jsbmb.2004.12.010, 15860254.
9. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006, 47:312-318. 10.1161/01.HYP.0000201443.63240.a7, 16432039.
10. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108:465-474. 10.1016/S0092-8674(02)00641-4, 11909518.
11. Nagy L, Schwabe JW. Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 2004, 29:317-324. 10.1016/j.tibs.2004.04.006, 15276186.
12. Simons SS. How much is enough? Modulation of dose-response curve for steroid receptor-regulated gene expression by changing concentrations of transcription factor. Current Topics in Medicinal Chemistry 2006, 6:271-285. 10.2174/156802606776173465, 16515481.
13. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006, 20:1405-1428. 10.1101/gad.1424806, 16751179.
14. Simons SS. What goes on behind closed doors: physiological versus pharmacological steroid hormone actions. Bioessays 2008, 30:744-756. 10.1002/bies.20792, 2742386, 18623071.
15. He Y, Simons SS. STAMP: a novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression. Mol Cell Biol 2007, 27:1467-1485. 10.1128/MCB.01360-06, 1800712, 17116691.
16. Szapary D, Song L-N, He Y, Simons SS. Differential modulation of glucocorticoid and progesterone receptor transactivation. Mol Cell Endocrinol 2008, 283:114-126. 10.1016/j.mce.2007.11.031, 2275900, 18215457.
17. Sun Y, Tao Y, Kagan BL, He Y, Simons SS. Modulation of transcription parameters in glucocorticoid receptor-mediated repression. Mol Cell Endocrinol 2008, 295:59-69. 10.1016/j.mce.2008.05.008, 2662735, 18583028.
18. Janke C, Rogowski K, Wloga D, Regnard C, Kajava AV, Strub JM, Temurak N, van Dijk J, Boucher D, van Dorsselaer A, Suryavanshi S, Gaertig J, Edde B. Tubulin polyglutamylase enzymes are members of the TTL domain protein family. Science 2005, 308:1758-1762. 10.1126/science.1113010, 15890843.
19. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36. 10.3322/canjclin.51.1.15, 11577478.
20. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
21. Leung EH, Leung PC, Auersperg N. Differentiation and growth potential of human ovarian surface epithelial cells expressing temperature-sensitive SV40 T antigen. In Vitro Cell Dev Biol Anim 2001, 37:515-521. 10.1290/1071-2690(2001)037<0515:DAGPOH>2.0.CO;2, 11669285.
22. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47. 10.3322/canjclin.52.1.23, 11814064.
23. Cvetkovic D. Early events in ovarian oncogenesis. Reprod Biol Endocrinol 2003, 1:68. 10.1186/1477-7827-1-68, 239895, 14577833.
24. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5:e232. 10.1371/journal.pmed.0050232, 2592352,2592352, 19053170.
25. Malek A, Schafer R, Tchernitsa O. Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer. Cancer Treat Rev
26. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schurmann P, Dork T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, Ouweland A, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093. 10.1038/nature05887, 2714974, 17529967.
27. Szapary D, Huang Y, Simons SS. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor regulated gene expression. Mol Endocrinol 1999, 13:2108-2121. 10.1210/me.13.12.2108, 10598585.
28. Chen S, Sarlis NJ, Simons SS. Evidence for a common step in three different processes for modulating the kinetic properties of glucocorticoid receptor-induced gene transcription. J Biol Chem 2000, 275:30106-30117. 10.1074/jbc.M005418200, 10899170.
29. Fonte C, Grenier J, Trousson A, Chauchereau A, Lahuna O, Baulieu EE, Schumacher M, Massaad C. Involvement of {beta}-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells. Proc Natl Acad Sci USA 2005, 102:14260-14265. 10.1073/pnas.0506930102, 1242324, 16186500.
30. Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S, Hormaeche I, McConnell MJ, Pierce S, Cole PA, Licht J, Zelent A. Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol 2005, 25:5552-5566. 10.1128/MCB.25.13.5552-5566.2005, 1156991, 15964811.
31. Santoso B, Kadonaga JT. Reconstitution of chromatin transcription with purified components reveals a chromatin-specific repressive activity of p300. Nat Struct Mol Biol 2006, 13:131-139. 10.1038/nsmb1048, 16415879.
32. Tao Y-G, Xu Y, Xu HE, Simons SSJ. Mutations of glucocorticoid receptor differentially affect AF2 domain activity in a steroid-selective manner to alter the potency and efficacy of gene induction and repression. Biochemistry 2008, 47:7648-7662. 10.1021/bi800472w, 2678802, 18578507.